CPPF, a novel microtubule targeting anticancer agent, inhibits the growth of a wide variety of cancers

Cited 2 time in scopus
Metadata Downloads
CPPF, a novel microtubule targeting anticancer agent, inhibits the growth of a wide variety of cancers
Ho Jin Han; Chanmi Park; Joonsung Hwang; N R Thimmegowda; Sun Ok Kim; Junyeol Han; Minsik Woo; B Shwetha; In Ja RyooKyung Ho LeeHyunjoo Cha; Y T Kwon; Bo Yeon KimNak Kyun Soung
Bibliographic Citation
International Journal of Molecular Sciences, vol. 21, no. 13, pp. 4800-4800
Publication Year
In the past, several microtubule targeting agents (MTAs) have been developed into successful anticancer drugs. However, the usage of these drugs has been limited by the acquisition of drug resistance in many cancers. Therefore, there is a constant demand for the development of new therapeutic drugs. Here we report the discovery of 5-5 (3-cchlorophenyl)-N-(3-pyridinyl)-2-furamide (CPPF), a novel microtubule targeting anticancer agent. Using both 2D and 3D culture systems, we showed that CPPF was able to suppress the proliferation of diverse cancer cell lines. In addition, CPPF was able to inhibit the growth of multidrug-resistant cell lines that are resistant to other MTAs, such as paclitaxel and colchicine. Our results showed that CPPF inhibited growth by depolymerizing microtubules leading to mitotic arrest and apoptosis. We also confirmed CPPF anticancer effects in vivo using both a mouse xenograft and a two-step skin cancer mouse model. Using established zebrafish models, we showed that CPPF has low toxicity in vivo. Overall, our study proves that CPPF has the potential to become a successful anticancer chemotherapeutic drug.
microtubule target agentanticancer drugskin cancer prevention/animal modelmultidrug resistanceCPPF
Appears in Collections:
Ochang Branch Institute > Chemical Biology Research Center > 1. Journal Articles
Ochang Branch Institute > Nucleic Acid Therapeutics Research Center > 1. Journal Articles
Files in This Item:

Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.